-
April 2, 2018
CMS Starts to Cover Broad Cancer DNA Tests, Boosting Foundation, ThermoBookmark
Emma Shtivelman, PhDExcerpt:
“The Centers for Medicare & Medicaid Services, which administers the federal Medicare insurance program, will begin covering FDA-approved diagnostic tests that scan tumors for a range of genetic mutations. The news is a boost for companies like Foundation Medicine and Thermo Fisher Scientific, who are among the few firms with such tests on the market.
“Late Friday, the CMS said that, going forward, it will start to reimburse for tests that use DNA sequencing technology to map the tumors of patients with advanced cancers once approved by the FDA. Two of the already-approved tests fitting this description are FoundationOne CDx, from Cambridge, MA-based Foundation, and Oncomine Dx Target Test, from Waltham, MA-based Thermo Fisher Scientific (NYSE: TMO). FoundationOne CDx looks for 324 cancer-related alterations in patients’ DNA. Foundation amasses a report based on the results and sends it to doctors, who use the data to suggest possible treatments. Oncomine detects 23 genetic alterations associated with non-small cell lung cancer.”
Go to full article published by Xconomy on Mar 19, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 16, 2018
Targetable Mutations in NSCLC: More Testing Needed!
Emma Shtivelman, PhDDiagnosis of adenocarcinoma of the lung, a major subtype of non-small lung cancer (NSCLC), nowadays triggers mandatory testing of tumor tissue for alterations in four genes: EGFR, ALK, ROS1, and more recently, BRAF. If present, these alterations predict sensitivity to… Read more »
-
December 5, 2017
FDA Approves First-of-a-Kind Test for Cancer-Gene ProfilingBookmark
Emma Shtivelman, PhDExcerpt:
“U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what’s driving a patient’s tumor and aiding efforts to match treatments to those flaws.
“The U.S. Food and Drug Administration approved Foundation Medicine’s test for patients with advanced or widely spread cancers, and the Centers for Medicare and Medicaid Services proposed covering it.
“The dual decisions, announced late Thursday, will make tumor-gene profiling available to far more cancer patients than the few who get it now and will lead more insurers to cover it.”
Go to full article by Houston Chronicle on Dec 2, 2017.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 31, 2017
The Trouble With KRAS
Emma Shtivelman, PhDMutations in the gene that encodes the KRAS protein are frequently encountered in various human cancers. They are found in about 30% of non-small cell lung cancers (NSCLCs), making KRAS the single most common gene mutated in this cancer. The… Read more »
-
April 4, 2017
Metastatic Melanoma: Not Quite Curable…But Getting There
Emma Shtivelman, PhDBy 2050, the number of deaths due to malignant melanoma in the U.S. could be three times lower than peak levels reached before 1960. Researchers presented the data behind this prediction at the 2017 European Cancer Congress in January. It… Read more »
-
February 7, 2017
Testing for Tumor Mutations: Liquid Biopsy Versus Traditional Biopsy
Emma Shtivelman, PhDUpdate as of August 27, 2020: A lot has changed in the three-and-a-half years since this blog post was written. Liquid biopsies are by now widely recognized and used as a valuable diagnostic and monitoring tool. Many of the reservations… Read more »
-
June 16, 2016
Lung Cancer Highlights from ASCO 2016
Emma Shtivelman, PhDThis year, the Annual Meeting of the American Society of Clinical Oncology (ASCO) did not produce any truly groundbreaking revelations about new treatments for lung cancer. However, researchers did report quite a few positive findings, and some disappointing ones.
-
October 30, 2015
To Type or to Print? Oncotype DX and Mamma/BluePrint Tests for Breast Cancer
Emma Shtivelman, PhDWomen diagnosed with localized breast cancer face difficult decisions with their doctors. What kind of neoadjuvant (before surgery) treatment to choose? Should chemotherapy follow surgery? Based on the subtype of breast cancer, should specific chemotherapy drugs be used?
-
September 9, 2015
To PD-L1 or Not to PD-L1: That Is the Question
Emma Shtivelman, PhDThese days, it seems that I write mostly about immune checkpoint blockade drugs, or some other new immunotherapy treatment for cancer. This post is no different—it covers PD-L1, a protein that is at the center of clinical decisions for selecting patients who are likely to benefit from treatment with an anti-PD-1 or anti-PD-L1 drug.
-
August 13, 2015
What Determines Whether a Melanoma Patient Will Respond to Checkpoint Blockade Drugs?
Emma Shtivelman, PhDOf all cancer types, melanoma is the most investigated in terms of its potential to be treated through immune system-based approaches. More immunotherapy drugs are approved for melanoma than for any other type of cancer, and more are in development. Recent additions to the immunotherapy arsenal are the ‘anti-PD-1’ immune checkpoint blockade drugs pembrolizumab (Keytruda) and nivolumab (Opdivo).